In addition, high-risk patients are accompanied by the upregulation of most immune checkpoints represented by PD-1/L1 and the increase in tumor mutation burden (TMB) and CNV, suggesting that patients may respond better to the ICI of PD-L1 (12–15). The gene discussed is CD274; the disease is neoplasm.